Skip to main content
. 2023 Jun 16;23:279. doi: 10.1186/s12886-023-03012-1

Table 2.

Baseline demographics and characteristics of patients in the alirocumab group with ≥ 2 consecutive LDL-C values < 25 mg/dL and propensity score-matched patients from the placebo group

All
(N = 8610)
Alirocumab
(N = 4305)
Placebo
(N = 4305)
Age, years 58.5 (9.3) 58.6 (9.2) 58.4 (9.4)
  < 65 years 6335 (73.6%) 3165 (73.5%) 3170 (73.6%)
 65 to < 75 years 1822 (21.2%) 911 (21.2%) 911 (21.2%)
  ≥ 75 years 453 (5.3%) 229 (5.3%) 224 (5.2%)
Male 6973 (81.0%) 3478 (80.8%) 3495 (81.2%)
Race
 White 6563 (76.2%) 3262 (75.8%) 3301 (76.7%)
 Asian 1436 (16.7%) 734 (17.0%) 702 (16.3%)
 Other/unknown 611 (7.1%) 309 (7.3%) 302 (7.0%)
Hispanic or Latino 1680 (19.5%) 858 (19.9%) 822 (19.1%)
Weight, kg 82.02 (16.68) 81.88 (16.69) 82.17 (16.68)
BMI, kg/m2 28.29 (4.68) 28.30 (4.70) 28.28 (4.66)
  ≥ 30 kg/m2 2721 (31.8%) 1344 (31.4%) 1377 (32.1%)
Region
 Asia 1359 (15.8%) 689 (16.0%) 670 (15.6%)
 South America 1443 (16.8%) 734 (17.0%) 709 (16.5%)
 Eastern Europe 2290 (26.6%) 1124 (26.1%) 1166 (27.1%)
 Western Europe 1869 (21.7%) 921 (21.4%) 948 (22.0%)
 North America 1088 (12.6%) 55 (12.9%) 534 (12.4%)
 Rest of world 561 (6.5%) 283 (6.6%) 278 (6.5%)

Data are presented as mean ± standard deviation or n (%)

BMI Body mass index